The group’s principal activity is to provide immunotherapeutics and oncology services. The group products sold under the trade names CroFab(R), DigiFab(R), Voraxaze(TM) and ViperaTAb(TM). The group’s operates through two segments namely sale, manufacture and development of pharmaceutical products and royalties arising from outlicensed technology. The group operates from the United Kingdom, the United States and Australia. Of the total revenue in the year 2006, sale, manufacture and development of pharmaceutical products accounted for $17,269and royalties arising from outlicensed technology $440 (thousands).
